1. Which of the following changes in cholesterol values was related to ensitrelvir treatment in a phase 2b study?
A. Decreased LDL
B. Increased LDL
C. Increased HDL
D. Decreased HDL
2. Which of the following diseases correlates positively with higher neutrophil-to-lymphocyte ratios and thereby correlates with severe COVID-19?
A. Asthma
B. Chronic obstructive pulmonary disease
C. Hyperlipidemia
D. Diabetes mellitus
3. Which of the following eye conditions has been recently associated with COVID-19 infection?
A. Conjunctivitis
B. Open-angle glaucoma
C. Closed-angle glaucoma
D. Optic neuritis
4. Decreases in post-COVID symptoms have been noted with ritonavir-boosted nirmatrelvir administration within how many days of a positive SARS-CoV-2 test?
A. 1
B. 3
C. 5
D. 7
5. Which of the following populations was excluded from recent cohort studies of molnupiravir and ritonavir-boosted nirmatrelvir showing decreased risk of long COVID-19?
A. Female sex
B. Previous COVID-19 infection or reinfection
C. Significant kidney disease (eGFR ≤30 mL/min)
D. Previous COVID-19 vaccination
6. A number of patients may be eligible for deprescribing of antidepressants that were originally prescribed during the pandemic. Which of the following symptoms is most likely upon discontinuation?
A. Agitation
B. Seizures
C. Hallucinations
D. Aseptic meningitis
7. A recent study evaluated the risk of cardiac adverse effects in young patients receiving COVID-19 vaccines as well as those who were positive for SARS-CoV-2. Which of the following cardiac effects was associated primarily with COVID-19 infection?
A. Preserved ejection heart failure
B. Reduced ejection heart failure
C. Myocarditis
D. Atrial fibrillation
8. Which of the following COVID-19 vaccines is no longer available in the United States?
A. Novavax protein vaccine
B. Pfizer mRNA bivalent vaccine
C. Moderna mRNA bivalent vaccine
D. Janssen adenovirus vaccine
9. Which of the following best describes a change in COVID-19 policy resulting from the end of the emergency declaration period in the United States?
A. All COVID-19–related medication treatment costs are now covered by the patient.
B. Cost-sharing is required for COVID-19 treatment for most patients with private insurance.
C. Uninsured patients continue to be covered 100% for COVID-19 testing and treatment.
D. Medicaid patients will be responsible for a copayment for COVID-19 vaccinations.
10. Which of the following patients should receive a dose of the parent (original) mRNA vaccine?
A. 20-year-old male who has received 1 dose of the parent Pfizer/BioNTech mRNA vaccine
B. 45-year-old female who has received 1 dose of the parent Moderna mRNA vaccine
C. 10-year-old female who has received 1 dose of the parent Pfizer/BioNTech mRNA vaccine
D. No patient should receive a dose of the parent mRNA vaccine
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Will the information presented cause you to change your practice?
A. Yes
B. No
21. Are you committed to making these changes?
A. Yes
B. No
22. As a result of this activity, did you learn something new?
A. Yes
B. No
23. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
24. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20